There were 573 press releases posted in the last 24 hours and 166,579 in the last 365 days.

Beta-lactam and Beta-lactamase Inhibitors Market to Reach $34.17 Billion by 2028 at 2.3% CAGR: AMR

Surge in consumption in low and middle-income countries (LMICs) and development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections drives the growth of the global beta-lactam and beta-lactamase inhibitors market. Based on region, Asia Pacific contributed largest revenue by contributing nearly two-fifths of the total market share in 2018.

/EIN News/ -- Portland, OR, Oct. 08, 2019 (GLOBE NEWSWIRE) -- The global beta-lactam and beta-lactamase inhibitors market garnered $27.12 billion in 2018 and is projected to reach $34.17 billion by 2028, registering a CAGR of 2.3% from 2019 to 2028. The report offers a detailed analysis of the key segments including top investment pockets, changing dynamics, market size & estimations, drivers and opportunities, and competitive scenario.

Request Report Sample at: https://www.alliedmarketresearch.com/request-sample/5427  

Increased consumption in low and middle-income countries (LMICs) and increase in prevalence of infectious diseases are the two major drivers for the growth of the global beta-lactam and beta-lactamase inhibitors market. Furthermore, development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections supplements the market growth. However, progress of beta-lactam resistance and longer approval time by the regulatory bodies are the factors that impede the market growth. On the other hand, discovery of advanced prospect molecules and new combination therapies to treat antibiotic-resistant microbial infections are expected to provide lucrative opportunities to the market.

Based on types of diseases, the respiratory infection segment held the largest share in 2018, contributing to nearly one-fourth of the total market share. The segment is expected to dominate throughout the forecast period. However, the complicated intra-abdominal infections (cIAI) segment is expected to register the fastest CAGR of 4.8% during the forecast period.

Based on route of administration, the intravenous segment held the largest share in 2018, accounting for more than half of the market share. Whereas, oral segment is projected to manifest the fastest CAGR of 2.7% during the forecast period.

Based on region, Asia Pacific dominated the market, contributing to nearly two-fifths of the market in 2018. The segment is estimated to secure the dominant position throughout the forecasting period. However, LAMEA is estimated to register the fastest CAGR of 3.6% during the study period.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/5427

The global beta-lactam and beta-lactamase inhibitors market report includes an in-depth analysis of the major market players such as F. Hoffmann-La Roche Ltd., Abbott Laboratories, Allergan Plc., GlaxoSmithKline plc, Novartis International AG (Sandoz), Merck & Co. Inc., Mylan N.V., Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada): 
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com 
Web: https://www.alliedmarketresearch.com

Primary Logo

Distribution channels: Book Publishing Industry, Science


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.